Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1A1 | Q02108 | 18/20 | 0.52 |
| ▸ | GUCY1B1 | Q02153 | 18/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.50 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL517421 | 0.88 | GUCY1A1 (0.44) | GUCY1A1GUCY1B1KCNH2PTPN11 | |
| SCHEMBL516959 | 0.87 | GUCY1A1 (0.43) | GUCY1A1GUCY1B1KCNH2PTPN11 | |
| SCHEMBL513757 | 0.85 | GUCY1A1 (0.42) | GUCY1A1GUCY1B1KCNH2 | |
| SCHEMBL517026 | 0.85 | GUCY1A1 (0.46) | GUCY1A1GUCY1B1KCNH2 | |
| SCHEMBL516308 | 0.85 | GUCY1A1 (0.42) | GUCY1A1GUCY1B1KCNH2PTPN11 | |
| SCHEMBL513758 | 0.84 | GUCY1A1 (0.43) | GUCY1A1GUCY1B1KCNH2 | |
| SCHEMBL516543 | 0.82 | GUCY1A1 (0.44) | GUCY1A1GUCY1B1KCNH2 | |
| SCHEMBL15378004 | 0.82 | GUCY1A1 (0.41) | GUCY1A1GUCY1B1KCNH2 | |
| SCHEMBL516207 | 0.82 | GUCY1A1 (0.40) | GUCY1A1GUCY1B1KCNH2PTPN11 | |
| SCHEMBL7901190 | 0.82 | GUCY1A1 (0.54) | GUCY1A1GUCY1B1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303559-A1 | BENZIMIDAZOLE AND PYRAZOLOPYRIDINE DERIVATIVES FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASES | BAYER IP GMBH (DE) | 2013-11-14 | — | — | US | disclosed |
| US-20120029002-A1 | BENZIMIDAZOLE AND PYRAZOLOPYRIDINE DERIVATIVES FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029002-A1 | BENZIMIDAZOLE AND PYRAZOLOPYRIDINE DERIVATIVES FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASES | PKM, BRD3, TNNI3 | GUCY1A1 3203/4885GUCY1B1 2537/4885KCNH2 302/4885 |
| US-20130303559-A1 | BENZIMIDAZOLE AND PYRAZOLOPYRIDINE DERIVATIVES FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASES | PKM, BRD3, TNNI3 | GUCY1A1 3203/4885GUCY1B1 2537/4885KCNH2 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.